Oct 15, 2024 | Benefits preservation, Biosimilar, Claims, Cost Savings, Drug costs, Rx Costs, Savings, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Oct 14, 2024 | Kurt Harden, MedBen Rx News, Pharmacogenomics, Precision medicine
On October 1, MedBen Chairman and CEO Kurt Harden spoke on the topic “A Third-Party Payer’s Approach to Providing Quality Care While Minimizing Cost” at the 2024 Ventegra Client Conference. Ventegra serves as MedBen Rx’s pharmacy benefits partner....
Oct 1, 2024 | Genomics, Kurt Harden, News, Nutrigenomics, Pharmacies, Pharmacogenomics, Wellness
MedBen Chairman & CEO Kurt Harden and Profero Team Director of Precision Medicine Cynthia Yu were featured presenters at the 11th Annual Sherrill-Morgan Healthcare Innovation Conference on September 18th. Harden and Yu spoke on the topic of genomic testing — what...
Sep 3, 2024 | Biosimilar, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Stelara, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Aug 15, 2024 | Food and Drug Administration (FDA), MDMA (ecstasy), Psychedelic drugs
The potential for psychedelic drugs to serve legitimate medical purposes has become a growing topic of discussion. On August 9, the Food and Drug Administration rejected midomafetamine (MDMA), better known as ecstasy, as a treatment for post-traumatic stress disorder....
